EP300 and neoplasm: We identified newly emerging mutations in genes that were not covered by our targeted NGS panel such as ATM, NOTCH2, EP300, ARID1A and MAP3K1 and also noticed an increase in tumor mutational burden (TMB) in some cases during progression (Fig. 3).